Skip to content
value.today

Convergent Therapeutics, Inc.

Total raised
$51 M
2 rounds on record
Latest round
$22 M
Jul 2024
First round on record
Apr 2023
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Convergent Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$22 MNo. 2$10 to $50 million

Convergent Therapeutics, Inc.: Raise no. 2, Jul 2024

Investors in this round

1 investor had bought by the notice of Aug 13, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $40 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander Brown · Executive Officer
  • Eric Sullivan · Executive Officer
  • Neil Bander · Executive Officer, Director
  • Philip Kantoff · Executive Officer, Director
  • Jake Simson · Director
  • Jim Trenkle · Director
  • Tal Zaks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philip Kantoff, Ceo. Newest notice filed Aug 13, 2024. Read the notice at the SEC.

equitySEC
Apr 2023$29 MNo. 1$10 to $50 million

Convergent Therapeutics, Inc.: Raise no. 1, Apr 2023

Investors in this round

15 investors had bought by the notice of May 22, 2023: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$29 M of $99 M offered; $70 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander Brown · Executive Officer
  • Philip Kantoff · Executive Officer, Director
  • Jake Simson · Director
  • Neil Bander · Director
  • Tal Zaks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philip Kantoff, Ceo. Newest notice filed May 22, 2023. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Convergent Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2024).

    SEC Form D · Aug 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Convergent Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Convergent Therapeutics, Inc.
NameRoleNamed in
Alexander BrownExecutive officerAug 2024
Eric SullivanExecutive officerAug 2024
Neil BanderExecutive officerAug 2024
Philip KantoffExecutive officerAug 2024
Jake SimsonDirectorAug 2024
Jim TrenkleDirectorAug 2024
Neil BanderDirectorAug 2024
Philip KantoffDirectorAug 2024
Tal ZaksDirectorAug 2024